Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled nitric oxide for right ventricular function in cardiogenic shock under VA-ECMO and Impella
jRCT1031250130Recruiting
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Aug 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of nitric oxide in cardiogenic shock and Right heart dysfunction (RHF), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Change in PAPi before and after inhaled nitric oxide. Started Aug 2025; status: recruiting.
02
Drugs
nitric oxide
03
Conditions
cardiogenic shockRight heart dysfunction (RHF)
Beyond the preview
Go deeper on jRCT1031250130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250130.